Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Latest News about JP:4523

Recent news which mentions JP:4523

Merck and Eisai say two lung-cancer trials failed to meet their main goals
Tickers ESAIY SPX
Tags JP:4523 ESAIY SPX
From MarketWatch
Eisai shares rise as FDA memo raises hopes for full approval of Alzheimer’s drug
Tags JP:4523
From MarketWatch
New Alzheimer’s drug could bring hope to patients, but could be out of reach for people on Medicare
Tickers BIIB
Tags BIIB JP:4523
From MarketWatch
Eli Lilly’s positive results from a Alzheimer’s trial seen as ‘potentially very important’
Tickers BIIB LLY
Tags BIIB LLY JP:4523
From MarketWatch
Healthcare merger mania scrutinized on Capitol Hill as new deal combines major health systems
Tickers BIIB
Tags JP:4523 BIIB
From MarketWatch
Veterans Health Administration will cover new Alzheimer’s drug. Why won’t Medicare?
Tickers BIIB
Tags BIIB JP:4523
From MarketWatch
Wall Street predicts approval for another ALS drug
Tickers AMLX BIIB IONS
Tags AMLX BIIB IONS
From MarketWatch
Medicare just crushed the hopes of 750,000 Alzheimer’s patients a year
Tickers BIIB SPX
Tags BIIB JP:4523 RUT
From MarketWatch
FDA approves Reata’s rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments
Tickers BIIB EWTX RETA SPX
Tags EWTX RETA SRPT
From MarketWatch
New Alzheimer’s drug shows some promise, but has big price tag
Tickers BIIB ESALF
Tags JP:4523 BIIB ESALF
From MarketWatch
Why the FDA didn’t grant an approval to Lilly’s Alzheimer’s drug
Tickers BIIB LLY SPX
Tags SPX BIIB LLY
From MarketWatch
Amid criticism for its handling of another Alzheimer’s drug, FDA will decide this week whether to approve lecanemab
Tickers BIIB LLY
Tags BIIB JP:4523 LLY
From MarketWatch
New Alzheimer’s drug appears to slow cognitive decline but is ‘not a breakthrough’
Tickers BIIB
Tags JP:4523 BIIB
From MarketWatch
5 things to know about the new Alzheimer’s drug — including why it may be risky for people who take blood thinners
Tickers BIIB SPX
Tags SPX BIIB JP:4523
From MarketWatch
Banks are short more than $1 trillion in capital, this analyst says, who fears the shortfall will only get worse
Tickers AMC AMGN APE BABA
Tags BIIB TSLA JP:4523
From MarketWatch
A new Alzheimer’s treatment may help some patients, though researchers say more safety data is needed
Tickers BIIB
Tags BIIB JP:4523
From MarketWatch
Eisai shares fall following report of patient death in Alzheimer’s trial
Tickers BIIB
Tags BIIB JP:4523
From MarketWatch
What to know about the Alzheimer’s drug data coming out this week
Tickers AXSM BIIB LLY MOR
Tags JP:4523 MOR BIIB
From MarketWatch
One Alzheimer’s drug has failed, but investors are still betting on Biogen and Lilly treatments
Tickers BIIB ESALF LLY MOR
Tags JP:4523 BIIB MOR
From MarketWatch
Biogen and Eisai make plans to take another Alzheimer’s drug to the FDA
Tickers BIIB SPX
Tags SPX BIIB JP:4523
From MarketWatch
Medicare coverage of Eisai and Biogen’s promising new Alzheimer’s therapy is ‘another bridge to cross’
Tickers BIIB ESALF SPX
Tags BIIB JP:4523 ESALF
From MarketWatch
Here’s why one strategist says the consumer and related stocks might get a second wind
Tickers AAPL AMC AMZN APE
Tags NIO BTCUSD GBPUSD
From MarketWatch
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer’s drug success
Tickers BIIB LLY
Tags LLY JP:4523 BIIB
From MarketWatch
Eisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression
Tickers BIIB ESALY
Tags JP:NIK ESALY BIIB
From MarketWatch
Alzheimer’s drug from Eisai, Biogen shows promise in large trial
Tickers BIIB
Tags BIIB JP:4523
From MarketWatch
Eisai shares sink after Japan regulators seek more data for review of Alzheimer’s drug
Tickers BIIB
Tags JP:4523 BIIB
From MarketWatch
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.